EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections
SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care.
- Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano.
- By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms.
- EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance.
- By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease.